On The Fly
| ShowHide Related Items >><< TPTX Turning Point Therapeutics - 06/03/22
- Turning Point Therapeutics jumps 117% to $74.16 after Bristol-Myers buyout offer
- 06/03/22
- Bristol-Myers to acquire Turning Point Therapeutics for $76.00 per share
- 06/03/22
- Bristol-Myers to acquire Turning Point Therapeutics for $76.00 per share
- 05/16/22
- Turning Point Therapeutics appoints Steve Sabus as CCO
SWTX SpringsWorks Therapeutics - 05/26/22
- SpringsWorks Therapeutics presents Nirogacestat Clinical Data at 2022 ASCO
- 05/24/22
- SpringsWorks Therapeutics: Nirogacestat achieved endpoints in Phase 3 DeFi trial
- 04/19/22
- SpringsWorks announces agreeement with Regeneron for nirogacestat
- 12/10/21
- SpringsWorks Therapeutics announces trial collaboration with AbbVie
- 05/04/22
- Spotify introduces 'Spotify Island' on Roblox
- 04/27/22
- Spotify falls -11.2%
- 04/27/22
- Spotify falls -8.7%
- 04/27/22
- Spotify: Guidance reflects full closure of services in Russia
- 02/28/22
- Semrush plans acquisition of Austin-based Kompyte, no terms
- 01/19/22
- Semrush acquires Backlinko.com, terms not disclosed
RVMD Revolution Medicines - 03/24/22
- Revolution Medicines director buys $5.49M in common stock
- 05/26/22
- PMV Pharmaceuticals: Lead program, PC14586 accepted as oral presentation at ASCO
- 04/27/22
- PMV Pharmaceuticals to present initial PC14586 Phase 1 data at ASCO
- 06/02/22
- Lululemon reports Q1 SSS up 28% or up 29% on constant FX
- 05/10/22
- Nielsen selected by Lululemon as Marketing Mix Modeling provider
- 04/21/22
- Xponential Fitness enters collaboration with Lululemon, MIRROR
- 04/20/22
- Lululemon announces five year growth plan to double revenue to $12.5B by 2026
- 06/06/22
- Carl Icahn to discontinue proxy contest waged at Kroger, withdraw nominees
- 05/25/22
- Kroger expands Fulfillment Network to Central Ohio
- 05/09/22
- Else Nutrition receives formal listing approval for cereals on Kroger.com
- 05/17/22
- GoodRx announces strategic relationship with RxVantage
- 05/09/22
- GoodRx 'unlikely' to achieve guidance provided on Q4 earnings call
- 05/09/22
- GoodRx names former Uber grocery, new verticals chief Raj Beri as COO
- 05/02/22
- GoodRx partners with AssistRx
- 05/10/22
- L.B. Foster sees funding operations in 2022 and beyond
- 03/01/22
- L.B. Foster maintains 'optimistic outlook' regarding long-term trends
- 12/09/21
- Edison International raises quarterly dividend to 70c per share
- 03/30/22
- Dun & Bradstreet to divest business-to-consumer marketing business in Germany
- 02/16/22
- Dun & Bradstreet announce 10-year strategic agreement
- 02/15/22
- Cannae Holdings sells 20% interest in Optimal Blue to Black Knight for $578M
- 01/13/22
- Dun & Bradstreet to make operational changes, refunds to settle FTC charges
- 05/20/22
- DoorDash discloses $400M share repurchase program
- 05/16/22
- Lone Pine adds TSMC in Q1, exits KE Holdings and Adobe
- 05/12/22
- Instacart announces confidential submission of draft registration statement
- $164.16 /
+2.095 (+1.29%) - 05/16/22
- Tiger Global buys Starry, exits Adobe in Q1
- 04/08/22
- Crowdstrike targets over $5B in annual recurring revenue
- 04/07/22
- Crowdstrike announces IL-4 authorization to protect DOD assets
- 04/07/22
- Crowdstrike, Mandiant announce strategic partnership
- 06/06/22
- Bristol-Myers reports three-year data from Phase 3 CheckMate -9LA trial
- 06/06/22
- Bristol-Myers reports five-year data from Phase 3 CheckMate -227 trial
- 06/03/22
- Bristol-Myers withdraws sBLA for Reblozyl
- 06/06/22
- Bausch + Lomb announces seven presentations on Biotrue products
- 06/02/22
- Bausch + Lomb announces U.S. launch of Biotrue Hydration Plus Solution
- 05/24/22
- Bausch + Lomb receives Health Canada approval for Lumify
- 05/12/22
- Bausch + Lomb release survey findings on macular edema treatment
- 05/16/22
- Berkshire Hathaway adds Citi, exits Wells Fargo in Q1
- 05/10/22
- American Express partners with Versapay for accounts receivable experience
- 04/28/22
- American Express enters integration collaboration with Billtrust
- 04/13/22
- Bread Financial launches new consumer credit card
- 06/03/22
- Aurora Cannabis repurchases $20M of convertible senior notes
- 05/18/22
- Aurora Cannabis receives EU-GMP certification for facility in Germany
- 05/12/22
- Aurora Cannabis raises expense savings target to C$150M-C$170M
- 03/22/22
- Aurora Cannabis to acquire Thrive Cannabis for $38M
- 06/06/22 Raymond James
- Raymond James upgrades Spotify to buy with bad news priced in
- 06/06/22 Raymond James
- Spotify upgraded to Outperform from Market Perform at Raymond James
- 04/29/22 Citi
- Spotify price target lowered to $165 from $240 at Citi
- 04/28/22 Truist
- Spotify price target lowered to $150 from $210 at Truist
- $164.16 /
+2.095 (+1.29%) - 06/06/22 Morgan Stanley
- Crowdstrike upgraded to Overweight from Equal Weight at Morgan Stanley
- 06/03/22 Morgan Stanley
- Crowdstrike price target raised to $195 from $181 at Morgan Stanley
- 06/03/22 Jefferies
- Crowdstrike price target raised to $215 from $200 at Jefferies
- 06/03/22 DA Davidson
- Crowdstrike price target lowered to $235 from $280 at DA Davidson
- 06/06/22 Barclays
- Lululemon price target lowered to $435 from $450 at Barclays
- 06/06/22 Bernstein
- Lululemon upgraded to Market Perform from Underperform at Bernstein
- 06/03/22 UBS
- Lululemon price target lowered to $365 from $430 at UBS
- 06/03/22 Morgan Stanley
- Lululemon Q1 results 'speak for themselves,' says Morgan Stanley
- 06/06/22 Raymond James
- DoorDash initiated with a Market Perform at Raymond James
- 06/03/22 DA Davidson
- DoorDash price target lowered to $82 from $135 at DA Davidson
- 06/02/22 JMP Securities
- DoorDash price target lowered to $150 from $200 at JMP Securities
- 06/02/22 Truist
- DoorDash price target lowered to $185 from $200 at Truist
- 06/06/22 Stifel
- Aurora Cannabis upgraded to Hold from Sell at Stifel
- 05/16/22 CIBC
- Aurora Cannabis price target lowered to C$3.75 from C$6.50 at CIBC
- 05/13/22 Cantor Fitzgerald
- Aurora Cannabis price target lowered to C$3.90 from C$7.60 at Cantor Fitzgerald
- 04/01/22 Alliance Global Partners
- Senate remains the hurdle for MORE Act, says Alliance Global Partners
- 06/06/22 Edward Jones
- American Express upgraded to Buy from Hold at Edward Jones
- 05/12/22 Wolfe Research
- Wolfe downgrades credit card issuers on 80% probability of recession
- 05/12/22 Wolfe Research
- American Express downgraded to Peer Perform from Outperform at Wolfe Research
- 04/26/22 Citi
- American Express price target raised to $190 from $187 at Citi
TPTX Turning Point Therapeutics - 06/06/22 Cowen
- Turning Point Therapeutics downgraded to Market Perform from Outperform at Cowen
- 06/06/22 H.C. Wainwright
- Turning Point Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- 06/05/22 BofA
- BofA keeps Buy on Bristol-Myers, raises price target to $80
- 06/03/22 Oppenheimer
- Turning Point Therapeutics downgraded to Perform from Outperform at Oppenheimer
- 06/03/22 Stifel
- Bristol-Myers' offer for Turning Point Therapeutics 'fair,' says Stifel
- 03/02/22 Oppenheimer
- Oppenheimer upgrades PMV Pharmaceuticals to Outperform with $30 price target
- 03/02/22 Oppenheimer
- PMV Pharmaceuticals upgraded to Outperform from Perform at Oppenheimer
- 09/22/21 Goldman Sachs
- PMV Pharmaceuticals upgraded to Buy from Neutral at Goldman Sachs
SWTX SpringsWorks Therapeutics - 06/06/22 H.C. Wainwright
- SpringsWorks price target lowered to $95 from $142 at H.C. Wainwright
- 05/27/22 Wedbush
- SpringsWorks Therapeutics price target lowered to $50 from $110 at Wedbush
- 05/24/22 Goldman Sachs
- SpringsWorks Therapeutics price target raised to $82 from $76 at Goldman Sachs
RVMD Revolution Medicines - 05/20/22 BofA
- BofA starts Revolution Medicines at Neutral with $24 price target
- 05/20/22 BofA
- Revolution Medicines initiated with a Neutral at BofA
- 03/01/22 Stifel
- Stifel upgrades Revolution Medicines, sees good entry point after pullback
- 06/06/22 B. Riley
- L.B. Foster downgraded to Neutral on inflation headwinds at B. Riley
- 06/06/22 B. Riley
- L.B. Foster downgraded to Neutral from Buy at B. Riley
- 03/10/22 B. Riley
- L.B. Foster price target lowered to $18 from $21 at B. Riley
- 08/04/21 B. Riley
- L.B. Foster price target raised to $21 from $19 at B. Riley
- 06/06/22 UBS
- Edison International downgraded to Neutral from Buy at UBS
- 06/06/22 UBS
- Edison International downgraded to Neutral from Buy at UBS
- 05/10/22 Mizuho
- Edison International downgraded to Neutral from Buy at Mizuho
- 05/04/22 Citi
- Edison International price target raised to $79 from $67 at Citi
- 06/06/22 RBC Capital
- Dun & Bradstreet downgraded to Sector Perform from Outperform at RBC Capital
- 06/06/22 RBC Capital
- Dun & Bradstreet downgraded to Sector Perform from Outperform at RBC Capital
- 05/17/22 Barclays
- Dun & Bradstreet price target lowered to $18 from $22 at Barclays
- 05/10/22 Needham
- Dun & Bradstreet price target lowered to $21 from $28 at Needham
- 06/06/22 BofA
- GoodRx reinstated with a Buy at BofA
- 06/01/22 Baird
- Baird downgrades GoodRx to Neutral amid disruption at Kroger
- 06/01/22 Baird
- GoodRx downgraded to Neutral from Outperform at Baird
- 05/16/22 Baird
- Baird 'hypothesizing' GoodRx PBM/pharmacy issue at Kroger may be improving
- 06/06/22 Guggenheim
- Kroger price target raised to $57 from $49 at Guggenheim
- 06/02/22 Deutsche Bank
- Kroger price target raised to $50 from $49 at Deutsche Bank
- 06/06/22 Citi
- Bausch + Lomb initiated with a Buy at Citi
- 05/31/22 Jefferies
- Bausch + Lomb initiated with a Buy at Jefferies
- 05/31/22 BofA
- Bausch + Lomb initiated with a Buy at BofA
- 05/31/22 Deutsche Bank
- Bausch + Lomb initiated with a Hold at Deutsche Bank
- 06/06/22 Morgan Stanley
- Semrush initiated with an Equal Weight at Morgan Stanley
- 05/12/22 KeyBanc
- KeyBanc downgrades Semrush to Sector Weight on relocation, SMB risks/expenses
- 05/12/22 KeyBanc
- Semrush downgraded to Sector Weight from Overweight at KeyBanc
- 05/12/22 Jefferies
- Semrush price target lowered to $10 from $15 at Jefferies
- 06/06/22 Stephens
- Hanover Bancorp initiated with an Overweight at Stephens
- 06/06/22 Piper Sandler
- Hanover Bancorp initiated with an Overweight at Piper Sandler
SLGBF Good Natured Products - 06/06/22 Raymond James
- Good Natured Products downgraded to Market Perform from Outperform at Raymond James
- 12/14/21 National Bank
- Good Natured Products initiated with an Outperform at National Bank
- 11/02/21 Raymond James
- Good Natured Products price target lowered to C$1.50 from C$2 at Raymond James
- 10/29/21 Canaccord
- Good Natured Products price target lowered to C$1.20 from C$1.90 at Canaccord
TPTX Turning Point Therapeutics - 05/10/22
- Turning Point Therapeutics reports Q1 EPS ($1.50), consensus ($1.51)
- 02/28/22
- Turning Point Therapeutics reports Q4 EPS ($1.58), consensus ($1.39)
SWTX SpringsWorks Therapeutics - 05/05/22
- SpringsWorks Therapeutics reports Q1 EPS ($1.26), consensus ($1.02)
- 02/24/22
- SpringsWorks Therapeutics reports Q4 EPS ($1.15), consensus (88c)
- 04/27/22
- Spotify sees Q2 revenue EUR 2.8B, MAUs 428M
- 04/27/22
- Spotify reports Q1 EPS EUR 0.21 vs. (EUR 0.25) last year
- 02/02/22
- Spotify reports Q4 EPS (EUR0.21) vs (EUR0.66) last year
- 05/10/22
- Semrush sees FY22 revenue $249M-$251M, consensus $244.94M
- 05/10/22
- Semrush sees Q2 revenue $59.5M-$60.5M, consensus $59.03M
- 05/10/22
- Semrush reports Q1 EPS (2c), consensus (3c)
- 02/28/22
- Semrush sees FY22 revenue $245M-$247M, consensus $237.4M
RVMD Revolution Medicines - 05/09/22
- Revolution Medicines sees FY22 GAAP net loss $260M-$290M
- 05/09/22
- Revolution Medicines reports Q1 EPS (78c), consensus (77c)
- 02/28/22
- Revolution Medicines reports Q3 EPS (71c), consensus (64c)
- 05/10/22
- PMV Pharmaceuticals reports Q1 EPS (41c), consensus (40c)
- 03/01/22
- PMV Pharmaceuticals reports 2021 EPS ($1.28), consensus ($1.22)
- 06/02/22
- Lululemon raises FY22 EPS view to $9.35-$9.50 from $9.15-$9.35, consensus $9.28
- 06/02/22
- Lululemon sees Q2 EPS $1.89-$1.94, consensus $1.77
- 06/02/22
- Lululemon reports Q1 EPS $1.48, consensus $1.43
- 03/03/22
- Kroger sees FY22 adjusted EPS $3.75-$3.85, consensus $3.45
- 03/03/22
- Kroger reports Q4 adjusted EPS 91c, consensus 74c
- 03/02/22
- Notable companies reporting before tomorrow's open
- 05/09/22
- GoodRx sees Q2 revenue about $190M, consensus $215.62M
- 05/09/22
- GoodRx reports Q1 adjusted EPS 10c, consensus 8c
- 05/09/22
- Notable companies reporting after market close
- 02/28/22
- GoodRx sees FY22 revenue growth roughly 23%, consensus $1.02B
- 05/10/22
- L.B. Foster reports Q1 EPS (15c), consensus (2c)
- 03/01/22
- L.B. Foster reports Q4 EPS (3c), two estimates 19c
- 05/03/22
- Edison International backs FY22 EPS view of $4.40-$4.70, consensus $4.51
- 05/03/22
- Edison International reports Q1 EPS $1.07, consensus 79c
- 02/24/22
- Edison International sees FY22 core EPS $4.40-$4.70, consensus $4.56
- 02/24/22
- Edison International reports Q4 core EPS $1.16, consensus $1.04
- 05/09/22
- Dun & Bradstreet sees FY22 adjusted EPS $1.13-$1.20, consensus $1.15
- 05/09/22
- Dun & Bradstreet reports Q1 adjusted EPS 24c, consensus 23c
- 02/16/22
- Dun & Bradstreet reports Q4 EPS (3c) consensus 3c
- 05/05/22
- DoorDash reports Q1 EPS (48c), consensus (41c)
- 05/05/22
- Notable companies reporting after market close
- 02/16/22
- DoorDash reports Q4 EPS (45c), consensus (25c)
- 02/16/22
- Notable companies reporting after market close
- $164.16 /
+2.095 (+1.29%) - 06/02/22
- CrowdStrike raises FY23 EPS view to $1.18-$1.22 from $1.03-$1.13
- 06/02/22
- CrowdStrike sees Q2 adjusted EPS 27c-28c, consensus 24c
- 06/02/22
- CrowdStrike reports Q1 adjusted EPS 31c, consensus 23c
- 06/02/22
- Notable companies reporting after market close
- 04/29/22
- Bristol-Myers lowers FY22 adjusted EPS view to $7.44-$7.74 from $7.65-$7.95
- 04/29/22
- Bristol-Myers reports Q1 EPS $1.96, consensus $1.91
- 04/28/22
- Notable companies reporting before tomorrow's open
- 05/10/22
- Bausch Health sees 2022 revenue $8.25B-$8.4B, consensus $8.57B
- 04/22/22
- American Express reports Q1 EPS $2.73, consensus $2.44
- 02/27/22
- Berkshire operating earnings surge, Buffett repurchases record $27B in stock
- 01/25/22
- American Express sees FY22 EPS $9.25-$9.65, consensus $9.67
- 01/25/22
- American Express reports Q4 EPS $2.18, consensus $1.87
- 05/12/22
- Aurora Cannabis reports Q3 revenue C$50.43M vs. C$55.16M a year ago
- 02/10/22
- Aurora Cannabis reports Q2 adjusted EBITDA (C$9M) vs. (C$11.5) in Q1
- 02/10/22
- Aurora Cannabis reports Q2 revenue C$60.6M, vs. C$67.67M a year ago
- 01/04/22
- Aurora Cannabis to deliver C$10M cannabis shipment to Israel
|